In patients with hyperlipidemia, statins can inhibit HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthase, stimulating the cellular synthesis of LDL receptors (LDL-R), which increases the number and activity of LDL-R on the membrane surface of hepatocytes. Here, LDLR is linked to hyperlipidemia.